- The American Society of Clinical Oncologists (ASCO) is creating a “scorecard” by rating cancer drugs based on numerous clinical and financial factors.
- ASCO Chief Medical Office, Richard Schilsk, wants to address the disconnect between drug prices and true therapeutic value.
- ASCO would like oncologists to consult the scorecard when making treatment decisions.
The ASCO scorecard will be an algorithm, that helps assess the value of cancer treatment options. It takes into effect clinical benefit, side effects, quality of life, overall survival, progression free survival, costs and other factors.